Page 18 - Solid Tumors News Today

The topics included clinical staging of colorectal cancer, FDA approvals, and a study published in the print version of the American Journal of Managed Care®.

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) has earned an average rating of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month price objective […]

Maurie Markman, MD, discusses current challenges faced with developing robust decision support tools for oncologists and projects additional research efforts dedicated to finding a way to leverage CAR T-cell therapies in solid tumors to improve patient outcomes.

Mizuho started coverage on shares of Kura Oncology (NASDAQ:KURA – Free Report) in a report published on Friday morning, Marketbeat reports. The brokerage issued a buy rating and a $26.00 price objective on the stock. Other equities analysts have also issued reports about the stock. Cantor Fitzgerald restated an overweight rating and set a $30.00 […]

Shares of Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month […]

Bristol Myers Squibb on Tuesday announced a deal to acquire RayzeBio in an effort to expand the drugmaker’s cancer treatment offerings. The acquisition was for a total equity value of about $4.1 billion, at $62.50 per share. RayzeBio, a clinical-stage radiopharmaceutical therapeutics (RPT) company, has several cancer treatments under development, specifically ones targeting the treatment…

Johnson & Johnson announced that it has applied to the FDA for approval of Rybrevant in combination with lazertinib as a first-line treatment for adult patients with EGFR-mutated locally advanced or...

News Release Media Contacts: Zayn Qureshi +44 7760 334666 Email: zqureshi@its.jnj.com Investor...

A supplemental biologics license application and new drug application seeking the approval of amivantamab plus lazertinib as frontline therapy for the treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations have been submitted to the FDA.

In this article, Cerba details how AI and image analysis were using in the quantification of Ki-67 in solidtumors.